Priority Review was granted by FDA for the first line metastatic TNBC treatment. Datroway significantly improved survival ...
AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Datroway (datopotamab deruxtecan) has been accepted and granted ...
The sBLA is supported by results from the pivotal phase 3 TROPION-Breast02 clinical trial (NCT05374512), which evaluated the efficacy and safety of Dato-DXd compared with the investigator’s choice of ...
The FDA has accepted and granted priority review to a supplemental biologics license for datopotamab deruxtecan-dlnk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results